Dimension Therapeutics Inc. (NASDAQ:DMTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday.

According to Zacks, “Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company’s pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts. “

A number of other equities research analysts have also issued reports on the stock. Jefferies Group set a $12.00 target price on shares of Dimension Therapeutics and gave the stock a “buy” rating in a report on Monday, September 12th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Dimension Therapeutics in a report on Wednesday, June 22nd. Canaccord Genuity set a $20.00 target price on shares of Dimension Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 11th. Finally, Chardan Capital set a $10.00 target price on shares of Dimension Therapeutics and gave the stock a “hold” rating in a report on Sunday, August 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $17.19.

Analyst Recommendations for Dimension Therapeutics (NASDAQ:DMTX)

Shares of Dimension Therapeutics (NASDAQ:DMTX) traded up 4.56% during midday trading on Monday, reaching $7.34. 35,626 shares of the company were exchanged. The firm has a 50-day moving average of $7.69 and a 200 day moving average of $7.47. The firm’s market capitalization is $183.71 million. Dimension Therapeutics has a 52 week low of $5.39 and a 52 week high of $15.55.

Dimension Therapeutics (NASDAQ:DMTX) last released its earnings results on Thursday, August 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.06. Dimension Therapeutics had a negative return on equity of 66.58% and a negative net margin of 459.47%. On average, equities research analysts expect that Dimension Therapeutics will post ($1.91) EPS for the current year.

Several large investors have recently made changes to their positions in the stock. BlackRock Institutional Trust Company N.A. raised its stake in shares of Dimension Therapeutics by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 29,152 shares of the company’s stock worth $228,000 after buying an additional 89 shares in the last quarter. Teachers Advisors Inc. raised its position in shares of Dimension Therapeutics by 224.3% in the second quarter. Teachers Advisors Inc. now owns 19,204 shares of the company’s stock valued at $115,000 after buying an additional 13,283 shares during the period. California State Teachers Retirement System raised its position in shares of Dimension Therapeutics by 113.2% in the second quarter. California State Teachers Retirement System now owns 25,634 shares of the company’s stock valued at $154,000 after buying an additional 13,610 shares during the period. Bank of New York Mellon Corp raised its position in shares of Dimension Therapeutics by 180.8% in the second quarter. Bank of New York Mellon Corp now owns 28,743 shares of the company’s stock valued at $173,000 after buying an additional 18,506 shares during the period. Finally, Highbridge Capital Management LLC bought a new position in shares of Dimension Therapeutics during the second quarter valued at $123,000. 85.80% of the stock is owned by hedge funds and other institutional investors.

About Dimension Therapeutics

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

5 Day Chart for NASDAQ:DMTX

Receive News & Stock Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related stocks with our FREE daily email newsletter.